396092-84-5

Usage

Uses

Used in Organic Synthesis:
4-N,N-Dimethylamino-2-(tributylstannyl)-pyridine is used as a reagent for the synthesis of functionalized pyridines and other heterocyclic compounds. Its unique structure allows for versatile applications in organic synthesis, facilitating the creation of a wide range of chemical products.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 4-N,N-Dimethylamino-2-(tributylstannyl)-pyridine is used as a key intermediate in the synthesis of various pharmaceuticals. Its ability to participate in nucleophilic substitution and coordination with metal catalysts makes it a valuable tool for the development of new drugs.
Used in Agrochemical Synthesis:
4-N,N-Dimethylamino-2-(tributylstannyl)-pyridine is also utilized in the agrochemical industry for the synthesis of pesticides and other agrochemicals. Its versatility in organic synthesis contributes to the development of effective and targeted agrochemical products.
Used in Materials Science:
In the field of materials science, 4-N,N-Dimethylamino-2-(tributylstannyl)-pyridine is employed in the synthesis of advanced materials with specific properties. Its unique structure and reactivity contribute to the creation of materials with potential applications in various industries.
It is crucial to handle and dispose of 4-N,N-Dimethylamino-2-(tributylstannyl)-pyridine with care, as tributylstannyl compounds are known to be toxic and can pose a risk to the environment if not managed properly.

Upstream product

• 1122-58-3 dmap 
• 1461-22-9 tributyltin chloride 

Downstream Products

• 457644-71-2 4-(N,N-dimethylamino)-2-(2,4-dinitrophenyl)pyridine 
• 1053216-42-4 4-(N,N-dimethylamino)-2-(2-nitrophenyl)pyridine 
• 85698-56-2 N⁴,N⁴,N^4',N^4'-tetramethyl-[2,2'-bipyridine]-4,4'-diamine 
• 457644-76-7 N-[5-acetylamino-2-(4-dimethylamino-pyridin-2-yl)-phenyl]-2,2-dimethyl-propionamide 
• 457644-75-6 N-[5-amino-2-(4-dimethylamino-pyridin-2-yl)-phenyl]-2,2-dimethyl-propionamide 
• 457644-69-8 2-(2,4-diaminophenyl)-4-(N,N-dimethylamino)pyridine 

Relevant academic research and scientific papers

Strategic Design of 2,2′-Bipyridine Derivatives to Modulate Metal-Amyloid-β Aggregation

The complexity of Alzheimer’s disease (AD) stems from the inter-relation of multiple pathological factors upon initiation and progression of the disease. To identify the involvement of metal-bound amyloid-β (metal-Aβ) aggregation in AD pathology, among the pathogenic features found in the AD-affected brain, small molecules as chemical tools capable of controlling metal-Aβ aggregation were developed. Herein, we report a new class of 2,2′-bipyridine (bpy) derivatives (1-4) rationally designed to be chemical modulators toward metal-Aβ aggregation over metal-free Aβ analogue. The bpy derivatives were constructed through a rational design strategy employing straightforward structural variations onto the backbone of a metal chelator, bpy: (i) incorporation of an Aβ interacting moiety; (ii) introduction of a methyl group at different positions. The newly prepared bpy derivatives were observed to bind to metal ions [i.e., Cu(II) and Zn(II)] and interact with metal-Aβ over metal-free Aβ to varying degrees. Distinguishable from bpy, the bpy derivatives (1-3) were indicated to noticeably modulate the aggregation pathways of Cu(II)-Aβ and Zn(II)-Aβ over metal-free Aβ. Overall, our studies of the bpy derivatives demonstrate that the alteration of metal binding properties as well as the installation of an Aβ interacting capability onto a metal chelating framework, devised via the rational structure-based design, were able to achieve evident modulating reactivity against metal-Aβ aggregation. Obviating the need for complicated structures, our design approach, presented in this work, could be appropriately utilized for inventing small molecules as chemical tools for studying desired metal-related targets in biological systems.

METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS

The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS

The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I' and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

Design of an Os Complex-Modified Hydrogel with Optimized Redox Potential for Biosensors and Biofuel Cells

Multistep synthesis and electrochemical characterization of an Os complex-modified redox hydrogel exhibiting a redox potential ≈+30 mV (vs. Ag/AgCl 3 m KCl) is demonstrated. The careful selection of bipyridine-based ligands bearing N,N-dimethylamino moieties and an amino-linker for the covalent attachment to the polymer backbone ensures the formation of a stable redox polymer with an envisaged redox potential close to 0 V. Most importantly, the formation of an octahedral N6-coordination sphere around the Os central atoms provides improved stability concomitantly with the low formal potential, a low reorganization energy during the Os3+/2+ redox conversion and a negligible impact on oxygen reduction. By wiring a variety of enzymes such as pyrroloquinoline quinone (PQQ)-dependent glucose dehydrogenase, flavin adenine dinucleotide (FAD)-dependent glucose dehydrogenase and the FAD-dependent dehydrogenase domain of cellobiose dehydrogenase, low-potential glucose biosensors could be obtained with negligible co-oxidation of common interfering compounds such as uric acid or ascorbic acid. In combination with a bilirubin oxidase-based biocathode, enzymatic biofuel cells with open-circuit voltages of up to 0.54 V were obtained.

Ru(II) complexes of tetradentate ligands related to 2,9-Di(pyrid-2′- yl)-1,10-phenanthroline

A series of 1,10-phenanthrolines were prepared having additional ligating substituents at the 2,9-positions. These substituents were either a 4-substituted pyrid-2-yl, quinolin-2-yl, 1,8-naphthyrid-2-yl, N-methyl imidazo-2-yl, or N-methyl benzimidazo-2-yl group. Additionally, 3,6-di-(pyrid-2′-yl)-dipyrido[3,2-a:2′,3′-c]phenazine was prepared. All but two of these ligands coordinated Ru(II) in a tetradentate equatorial fashion with two 4-methylpyridines bound in the axial sites. An X-ray structure analysis of the diimidazoyl system indicates considerable distortion from square planar geometry in the equatorial plane. Previously reported variations in the axial ligand for such complexes appear to have a stronger effect on the electronic absorption and redox properties of the system than similar changes in the equatorial ligand. In the presence of excess Ce(IV) as a sacrificial oxidant at pH 1, all the systems examined catalyze the decomposition of water to generate oxygen. Turnover numbers are modest, ranging from 146 to 416.